Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: FEBS J. 2015 Oct 26;282(24):4766–4781. doi: 10.1111/febs.13533

Figure 4.

Figure 4

p21WAF1/CIP1 expression following RAX knockdown. (A)Western blot of p21WAF1/CIP1 in shRNA-expressing αT3 cells following 72 h of puromycin. (B) Quantitative Odyssey® western blot of RAX and p21WAF1/CIP1 in αT3 cells infected with 3 TU/cell RAX (1199) shRNA or a non-targeting control (NT). (C) RAX expression level was quantitated from (B). (D) p21WAF1/CIP1 expression level was quantitated from (B). Data in (C) and (D) are shown as RAX or p21WAF1/CIP1 signal normalized to β tubulin relative to the average normalized signal from non-targeting control samples and shown as mean ± SEM (n=3); * denotes p < 0.05, ** denotes p < 0.01. (E) p21WAF1/CIP1 mRNA was quantified by real-time RT-PCR from cells used in (B). Data are shown as p21WAF1/CIP1 normalized to 18S rRNA. Results are shown as mean ± SEM (n=3). (F) Representative western blot of p21WAF1/CIP1 in WT and rax−/− pituitary from neonatal (14-day-old) mice. (G) Quantitation of western blots from WT and rax−/− pituitary from neonatal (14-day-old) mice, shown as mean ± SEM p21WAF1/CIP1 signal normalized to loading control, relative to wild type for each blot (n=6).